4-苄氧基二氢--3H-呋喃-2-酮 | 21034-22-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-苄氧基二氢--3H-呋喃-2-酮
• 中文别名: 4-苯甲酰基二氢-2(3H)-呋喃酮
• 英文名称: β-benzoyl-γ-butyrolactone
• 英文别名: 4-Benzoyl-2(3H)-dihydrofuranone；4-benzoyldihydrofuran-2(3H)-one；4-benzoyl-dihydro-furan-2-one；4-Benzoyl-dihydro-furan-2-on；(+/-)-4-benzoyldihydro-2(3H)-furanone；4-benzoyldihydro-2(3H)-furanone；4-benzoyloxolan-2-one
• CAS: 21034-22-0
• 化学式: C₁₁H₁₀O₃
• mdl: MFCD00463834
• 分子量: 190.199
• InChiKey: ZNOUXOIZMNTERL-UHFFFAOYSA-N

物化性质

• 熔点：
  62-64

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2932209090

反应信息

• 作为反应物：
  描述：

  4-苄氧基二氢--3H-呋喃-2-酮 以 甲醇 为溶剂， 反应 0.5h， 生成 3-Benzoyl-4-methoxybutanoic Acid
  参考文献：
  名称：

  Hydroxymethylation of 3-Aroylpropanoic Acids; An Improved Synthesis of 4-Aroyl-2(3H)-dihydrofuranones and an Easy Approach to 3-Aroyl-3-butenoic Acids

  摘要：

  DOI：

  10.1055/s-1980-29223
• 作为产物：
  描述：

  3-苯丙烯溴酸酯 在 盐酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 1.0h， 生成 4-苄氧基二氢--3H-呋喃-2-酮
  参考文献：
  名称：

  Chemistry of the Synthetic Strigolactone Mimic GR24

  摘要：

  这篇研究论文介绍了 (+)-GR24 的第二代对映选择性合成方法。这种新策略避免了臭氧分解的需要，因为臭氧分解可能不适合大规模进行的反应。这种灵活的新方法随后被用于合成一种新型溴-GR24 类似物。最后，确定了制造 GR24 储备溶液的最佳溶剂。

  DOI：

  10.1071/ch15298

文献信息

• THERAPEUTIC AGENT FOR DIABETES
  申请人：Japan Tobacco Inc.

  公开号：EP0885869A1

  公开（公告）日：1998-12-23

  A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4 and R5 are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6 is a hydrogen atom or an amino-protecting group; R1 is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2 is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3 is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.

  用于治疗糖尿病的疗法剂，包括公式[I]的化合物 其中 X是公式的组 其中R4和R5相同或不同，每个都是氢原子，可选地取代的具有1至5个碳原子的烷基等等，R6是氢原子或氨基保护基团；R1是具有1至5个碳原子的可选取代烷基，具有2至6个碳原子的可选取代烯基等等，R2是氢原子，具有1至5个碳原子的可选取代烷基等等，R2'是氢原子，R3是具有1至5个碳原子的可选取代烷基等等，其前药，药用可接受盐，水合物和溶剂化物。 本发明的化合物在血糖升高状态下表现出优越的降血糖作用，但在正常范围或低血糖状态下不影响血糖，这意味着它没有低血糖等严重副作用。因此，本发明的化合物作为治疗糖尿病的药物很有用，也用作预防糖尿病慢性并发症。
• Ureido-Pyridazinone Derivatives: Insights into the Structural and Conformational Properties for STAT3 Inhibition
  作者：Fiorella Meneghetti、Stefania Villa、Daniela Masciocchi、Daniela Barlocco、Lucio Toma、Dong-Cho Han、Byoung-Mog Kwon、Naohisa Ogo、Akira Asai、Laura Legnani、Arianna Gelain

  DOI：10.1002/ejoc.201500599

  日期：2015.8

  Three new ureido-pyridazinone derivatives, which are structurally related to the known STAT3 inhibitor AVS-0288, were designed by taking into account the structure–activity relationships determined for several ureido-oxadiazole derivatives previously studied by our group. Their synthesis was first attempted through suitable 5-aminopyridazinone intermediates (6a and 6b), which molecular structures were

  考虑到我们小组先前研究的几种脲基-恶二唑衍生物的构效关系，设计了三种新的脲基-哒嗪酮衍生物，它们在结构上与已知的 STAT3 抑制剂 AVS-0288 相关。它们的合成首先通过合适的 5-氨基哒嗪酮中间体（6a 和 6b）尝试合成，其分子结构通过 6a 的 X 射线衍射数据得到证实。胺官能化不成功，因此，设计了替代方法。双荧光素酶和基于 AlphaScreen 的测定被用来测试它们的活性。在建模研究的基础上对获得的数据进行了合理化，该研究将我们的注意力集中在脲基部分的几何偏好上。计算结果似乎表明 1,2,
• A facile synthesis of 3-aryl-4-pyrazoleacetic acids and of their 4,5-dihydro derivatives
  作者：Maria M. Curzu、Gérard A. Pinna、Daniela Barlocco、Giorgio Cignarella

  DOI：10.1002/jhet.5570270217

  日期：1990.2

  N-1-Unsubstituted-3-aryl-4-pyrazoleacetic acids and their 4,5-dihydro derivatives can conveniently be prepared by cyclization of 3-benzoyl-3-butenoic acids with hydrazine hydrate in acetic acid and subsequent treatment with bromine in acetic acid or, respectively, with diluted mineral acids.

  N -1-未取代的-3-芳基-4-吡唑乙酸及其4,5-二氢衍生物可以方便地通过将3-苯甲酰基-3-丁烯酸与水合肼在乙酸中环化，然后在溴中用乙酸处理而方便地制备。酸或稀无机酸。
• [EN] NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS<br/>[FR] DERIVES DE PYRROLE UTILISES COMME AGENTS PHARMACEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2002094833A1

  公开（公告）日：2002-11-28

  Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (I) is a four, five, or six membered saturated ring and X is C, O or S.

  小说吡唑衍生物化合物及其作为药物制剂的用途，特别是作为TGF-beta信号传导抑制剂的用途。所披露的发明涉及结构为（I）的化合物，其中（I）是四、五或六元饱和环，X为C，O或S。
• Novel pyrrole derivatives as pharmaceutical agents
  申请人：——

  公开号：US20040106604A1

  公开（公告）日：2004-06-03

  Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (I) is a four, five, or six membered saturated ring and X is C, O or S. 1

  小说吡唑衍生物化合物及其作为药物代理的使用，特别是其作为TGF-beta信号转导抑制剂的使用。所公开的发明涉及结构（I）的化合物，其中（I）是四、五或六个成员的饱和环，X是C、O或S。1